Alhadad A, Mattiasson I, Ivancev K, Gottsäter A, Lindblad B
Department of Vascular Diseases, University Hospital, University of Lund, Malmö, Sweden.
J Hum Hypertens. 2004 Oct;18(10):739-44. doi: 10.1038/sj.jhh.1001733.
We retrospectively evaluated short- and long-term effects of percutaneous transluminal renal angioplasty (PTRA) with or without stent placement of renal artery occlusion (RAO) upon blood pressure (BP), serum (s)-creatinine, and the need for antihypertensive treatment in 34 RAO patients who underwent PTRA during 1996-2002. In 24/34 (71%) treatment was considered technically successful, 22/24 (92%) were treated with PTRA + stent, two with only PTRA. Patients were followed for mean 2.6 (range 0-8) years, during which 14/34 (41%) patients died. In all 34 patients, systolic and diastolic BP (SBP and DBP) before treatment were 184 +/- 30/95 +/- 15 mmHg and had decreased at discharge (to 157 +/- 21/80 +/- 10 mmHg; P < 0.001 for both SBP and DBP), and remained lower after 1 year (154 +/- 20/83 +/- 7 mmHg; P < 0.001 for SBP and P < 0.01 for DBP), and at last follow-up (148 +/- 20/80 +/-12 mmHg; P < 0.001 for both SBP and DBP). No changes occurred in s-creatinine or the number of antihypertensive drugs. Similar results were seen in the subgroup of 24/34 (71%) patients in whom treatment was technically successful. Among the 24 patients undergoing technically successful PTRA, absence of nephrosclerosis (P = 0.035) and a shorter duration of hypertension (P = 0.020) predicted favourable clinical outcome. No adverse effects upon s-creatinine or the need for antihypertensive medication were seen in patients in whom treatment was considered a technical failure. Seven of these patients were treated with PTRA of another renal artery than the occluded, or with embolisation. In conclusion, RAO can be treated with endovascular techniques. Technically successful results with decreasing blood pressure levels were obtained in 71% of patients.
我们回顾性评估了1996年至2002年间接受经皮腔内肾血管成形术(PTRA)(伴或不伴肾动脉闭塞(RAO)支架置入)对34例RAO患者血压(BP)、血清肌酐及降压治疗需求的短期和长期影响。34例中有24例(71%)治疗在技术上成功,其中22例(92%)接受PTRA + 支架治疗,2例仅接受PTRA治疗。患者平均随访2.6年(范围0 - 8年),期间34例中有14例(41%)死亡。34例患者治疗前收缩压和舒张压(SBP和DBP)分别为184±30/95±15 mmHg,出院时下降(至157±21/80±10 mmHg;SBP和DBP均P < 0.001),1年后仍较低(154±20/83±7 mmHg;SBP P < 0.001,DBP P < 0.01),末次随访时亦如此(148±20/80±12 mmHg;SBP和DBP均P < 0.001)。血清肌酐及降压药物数量无变化。在技术上成功治疗的24/34例(71%)患者亚组中观察到类似结果。在24例技术上成功接受PTRA的患者中,无肾硬化(P = 0.035)及高血压病程较短(P = 0.020)预示良好临床结局。治疗被视为技术失败的患者中,未观察到血清肌酐或降压药物需求有不良反应。其中7例患者接受了与闭塞肾动脉不同的另一肾动脉的PTRA或栓塞治疗。总之,RAO可用血管内技术治疗。71%的患者获得了技术上成功且血压水平降低的结果。